Navigation Links
New Executive Leadership and CEO Announced for BiPar Sciences
Date:12/11/2009

BRIDGEWATER, N.J. and SOUTH SAN FRANCISCO, Calif., Dec. 11 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and its wholly-owned subsidiary, BiPar Sciences, today announced changes to the executive management team at BiPar Sciences.

BiPar Chief Executive Officer and President Hoyoung Huh, M.D., Ph.D. will take on a broader role in the sanofi-aventis organization as Chairman of the Board of Directors of BiPar, as well as chair of the newly formed BiPar Innovation Board. As part of this new role, Dr. Huh will serve as advisor to sanofi-aventis Chief Executive Officer Christopher A. Viehbacher and to Executive Vice President Research and Development Marc Cluzel, as well as to the Executive Committee, in the areas of innovation, R&D transformation, and entrepreneurship.

Sanofi-aventis has appointed Atul Dhir, M.D., Ph.D. as Chief Executive Officer of BiPar Sciences effective December 1, 2009. Dr. Dhir's mission is to continue developing the innovative BiPar portfolio, including the ongoing clinical program of BSI-201 - which, of an emerging class of investigational compounds (PARP inhibitors), is currently the furthest along in the Phase 3 clinical development in the metastatic triple negative breast cancer setting. As new Chief Executive Officer, Dr. Dhir will also be focused on maintaining the autonomy and entrepreneurial culture of BiPar, while capitalizing on the deep resources and experience of the worldwide sanofi-aventis organization.

Prior to joining BiPar, Dr. Dhir was a senior executive at US Oncology, one of the nation's largest cancer treatment and research networks. Previously, he had served as a vice president of the Healthcare Division of Monsanto and a consultant with McKinsey and Company.

About BiPar Sciences

BiPar Sciences is a biopharmaceutical organization dedicated to pioneering novel tumor-selective therapies designed to address urgent unmet needs of cancer patients. In addition to BSI-201, the company also has two additional compounds in preclinical development. BiPar Sciences, located in South San Francisco, California, is an independent, wholly-owned subsidiary of sanofi-aventis, Inc. For more information, please visit www.biparsciences.com.

About sanofi-aventis

Sanofi-aventis is a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the lives of patients. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York ( SNY).


Media Contacts:
---------------

Salah Mahyaoui
Global Communications
sanofi-aventis
Tel : +33 1 53 77 40 31
Mobile : +33 6 73 68 78 88
salah.mahyaoui@sanofi-aventis.com

Madeline Malia
U.S. Communications
sanofi-aventis
Tel: +1 908 981 5687
Mobile: +1 609 651 1323
madeline.malia@sanofi-aventis.com

SOURCE sanofi-aventis


'/>"/>
SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
2. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
3. Industry Executives Finding Value in Shift of Scientific Publications
4. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
5. Evalve Expands Executive Leadership Team
6. ParagonRx Names Ellen M. Derrico To Chief Marketing Executive Post
7. Tata Interactive Systems Partners With Bersin & Associates for Exclusive Executive Learning Forum - TLF 2009
8. Premier Research Appoints Troy W. McCall, Ph.D. as Chief Executive Officer
9. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
10. Lincare Holdings Inc. Extends Terms of Employment Agreements with Executive Officers
11. Curemark Announces Senior Executive Promotions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... SAN DIEGO and VANCOUVER, British Columbia, March 27, ... SPHS ) (the "Company" or "Sophiris"), a clinical ... treatment of patients with urological diseases, today reported ... and key corporate highlights. Key ... in Clinical Development for Localized Prostate Cancer. During ...
(Date:3/27/2017)... , March 27, 2017 /PRNewswire/ - INVICTUS MD ... IVITF; FRA: 8IS) Invictus MD is pleased to announce ... shares for trading on the TSX Venture Exchange.  ... TSXV follows a year of significant achievements for Invictus-MD. ... successful test crops at AB Laboratories Inc. ("AB Labs"), ...
(Date:3/27/2017)... , March 27, 2017 The ... reach USD 16.0 billion by 2025, according to a ... prevalence of chronic diseases is anticipated to be responsible ... which thereby widens the scope for growth during the ... bariatric population, which is highly susceptible to chronic diseases, ...
Breaking Medicine Technology:
(Date:3/28/2017)... Appleton, WI (PRWEB) , ... March 28, 2017 ... ... how self-funded health plans work, the Self-Funding Success website has recently developed and ... about Self-Funded Health Plans ” was created based on common inquiries the site’s ...
(Date:3/28/2017)... CA (PRWEB) , ... March 28, 2017 , ... ... Carson Liu of SkyLex Advanced Surgical, Inc. is thrilled to offer the recently ... balloon procedure, and this procedure adds to SkyLex Advanced Surgical’s already comprehensive ...
(Date:3/28/2017)... ... March 28, 2017 , ... Oily skin is a common and unwelcomed occurrence in people of ... a lot to offer to the discussion of dealing with excess skin oil. “Oily skin ... many home remedies that can help remove the oily shine while keeping the skin fresh ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have sleep apnea ... with or without a referral. Sleep apnea is often left untreated because patients are ... headaches and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep ...
(Date:3/27/2017)... Philadelphia PA and London UK (PRWEB) , ... ... ... have the speed, agility and ability to gain site attention and engagement over ... DrugDev educational webinar will discuss how partnering with the ...
Breaking Medicine News(10 mins):